Evidence map›Paper›PMID 41505630›Full record

ReviewCurrent opinion in urology2026

Biomarkers and testing in pathology.

Eva Compérat

Abstract readReview
In one paragraph

Review in Current opinion in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Eva CompératDepartment of Pathology, Medical University Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewWe try to highlight the most current testing methods in uropathology. Most of these tests are not fully approved, but nevertheless have found their way to daily routine. RECENT

findingsIn the bladder, testing is mainly based on immunohistochemistry and somatic testing. Other organs such as the prostate, the kidney, and the testis require sometimes different methods. SUMMARY: Although pathology is still the gold standard in diagnosis of tumor for patients in uropathology, many clinicians want to improve treatment options and try to tailor personalized treatments. This is of course depending not only on the available treatment options, but also on the somatic or germcell background of the patient and his tumor.

Indexed as

Biomarkers, TumorKidney NeoplasmsProstatic NeoplasmsUrinary Bladder NeoplasmsHumansImmunohistochemistryMaleBiomarkers, Tumorbladder cancerkidney cancerprostate cancertesting

Identifiers

PMID41505630
PMCPMC12893170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.